Search

Your search keyword '"Gragnano, Felice"' showing total 16 results
Start Over Author "Gragnano, Felice" Publisher lippincott williams & wilkins
16 results on '"Gragnano, Felice"'

3. Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology.

Author

Calabrò, Paolo, Spaccarotella, Carmen, Cesaro, Arturo, Andò, Giuseppe, Piccolo, Raffaele, De Rosa, Salvatore, Zimarino, Marco, Mancone, Massimo, Gragnano, Felice, Moscarella, Elisabetta, Muscoli, Saverio, Romeo, Francesco, Barillà, Francesco, Filardi, Pasquale Perrone, Indolfi, Ciro, and Niccoli, Giampaolo

Published
2023
Full Text
View/download PDF

4. Monitoring antiplatelet therapy: where are we now?

Author

Marcucci, Rossella, Berteotti, Martina, Gragnano, Felice, Galli, Mattia, Cavallari, Ilaria, Renda, Giulia, Capranzano, Piera, Santilli, Francesca, Capodanno, Davide, Angiolillo, Dominick J., Cirillo, Plinio, Calabrò, Paolo, Patti, Giuseppe, and De Caterina, Raffaele

Published
2023
Full Text
View/download PDF

5. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction

Author

Gargiulo, Giuseppe, Esposito, Giovanni, Avvedimento, Marisa, Nagler, Michael, Minuz, Pietro, Campo, Gianluca, Gragnano, Felice, Manavifar, Negar, Piccolo, Raffaele, Tebaldi, Matteo, Cirillo, Plinio, Hunziker, Lukas, VRANCKX, Pascal, Leonardi, Sergio, Heg, Dik, Windecker, Stephan, Valgimigli, Marco, and ESPOSITO, Giovanni/0000-0003-0565-7127

Subjects
prasugrel hydrochloride, tirofiban, platelet aggregation, percutaneous coronary intervention, cangrelor
Abstract

BACKGROUND: Standard administration of newer oral P2Y(12)inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. We aimed to investigate the effects of cangrelor, tirofiban, and prasugrel, administered as chewed or integral loading dose, on IPA in patients undergoing primary percutaneous coronary intervention. METHODS: The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, open-label, randomized study. A total of 122 P2Y(12)-naive patients with ST-segment-elevation myocardial infarction were randomly allocated (1:1:1) to cangrelor (n=40), tirofiban (n=40) (both administered as bolus and 2-hour infusion followed by 60 mg of prasugrel), or 60-mg loading dose of prasugrel (n=42). The latter group underwent an immediate 1:1 subrandomization to chewed (n=21) or integral (n=21) tablets administration. The trial was powered to test 3 hypotheses (noninferiority of cangrelor compared with tirofiban using a noninferiority margin of 9%, superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel as compared with integral prasugrel, each with alpha=0.016 for the primary end point, which was 30-minute IPA at light transmittance aggregometry in response to 20 mu mol/L adenosine diphosphate. RESULTS: At 30 minutes, cangrelor did not satisfy noninferiority compared with tirofiban, which yielded superior IPA over cangrelor (95.0 +/- 8.9 versus 34.1 +/- 22.5;P

Published
2020

6. Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease.

Author

Calabrò, Paolo, Gragnano, Felice, Niccoli, Giampaolo, Marcucci, Rossella, Zimarino, Marco, Spaccarotella, Carmen, Renda, Giulia, Patti, Giuseppe, Andò, Giuseppe, Moscarella, Elisabetta, Mancone, Massimo, Cesaro, Arturo, Giustino, Gennaro, De Caterina, Raffaele, Mehran, Roxana, Capodanno, Davide, Valgimigli, Marco, Windecker, Stephan, Dangas, George D., and Indolfi, Ciro

Subjects
*FIBRINOLYTIC agents, *HEART diseases, *PATENT foramen ovale, *TRICUSPID valve surgery, *TRICUSPID valve, *CARDIAC patients, *DRUG therapy for heart diseases, *PHARMACODYNAMICS
Abstract

Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.

Author

Gargiulo, Giuseppe, Esposito, Giovanni, Avvedimento, Marisa, Nagler, Michael, Minuz, Pietro, Campo, Gianluca, Gragnano, Felice, Manavifar, Negar, Piccolo, Raffaele, Tebaldi, Matteo, Cirillo, Plinio, Hunziker, Lukas, Vranckx, Pascal, Leonardi, Sergio, Heg, Dik, Windecker, Stephan, and Valgimigli, Marco

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results